Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Life Sciences Investment Opportunities Attract Cross Border Tie Ups

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - As China ramps up to overtake Japan as the No. 2 pharmaceutical market in coming years, investors are entering the foray to get a foothold in the burgeoning China pharma market and some interesting partners are joining forces

You may also be interested in...



What's The Winning Strategy In China? Franchises Are Key

Despite increasing concerns over protectionist policies in China, Morgan Stanley believes that market-based choices will trump government policies during the next decade, leading to success for multinational companies over the long term in the world's fastest-growing market

In China, Promotion Trumps Patents

HONG KONG - In the late 1980s, Warner-Lambert researcher Bruce Roth came up with atorvastatin and changed the pharmaceutical market, and social and healthcare awareness factors in the West that made Lipitor the biggest blockbuster ever are starting to show up in China and other Asian countries. Cholesterol, heart attacks and the gamut of cardiovascular diseases are on the rise as diets grow richer, lifestyles more sedentary and smoking remains prevalent

The Year Of The Tiger Looking Strong For IPOs In China Following Sinopharm Success

HONG KONG - Concerns over valuation seem to be doing little to dampen enthusiasm for new Chinese pharmaceutical related stocks and the result is a minefield of opportunities on very shaky ground

Related Content

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel